Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
P/B ratio for Ocugen, Inc. (OCGN)
P/B ratio as of 2023: 3.46
According to Ocugen, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.46. At the end of 2022 the company had a P/B ratio of 3.32.
P/B ratio history for Ocugen, Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.46 |
| 2022 | 3.32 |
| 2021 | 9.26 |
| 2020 | 9.53 |
| 2019 | 0.66 |
| 2018 | -7.13 |
| 2017 | -4.12 |
| 2016 | 1.75 |
| 2015 | 1.64 |
| 2014 | 0.31 |
| 2013 | -1.98 |
| 2012 | -7.60 |